The medication produces an agonist (a chemical) that acts as GLP-1 by binding itself to the appropriate cell receptors
Combination Therapy Enters the Competitive Field CagriSema (Novo Nordisk), a once weekly injectable combination of semaglutide and the longacting amylin analogue cagrilintide, is expected to receive FDA approval by late 2026
But at the same time, CMS has expanded the Medicare GLP-1 Bridge Program, which now runs July 1, 2026 through December 31, 2027 for eligible Medicare Part D beneficiaries
Treat these compounds with the same rigor you'd apply to any biologics in a temperature-controlled laboratory environmentbecause that's exactly what they are
Time to first ischemic stroke event in the follow-up was identified as a primary diagnosis of inpatient claims using the ICD-10-CM code I63 (except I63.1, I63.4, I63.6)